MedTrace Logo

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

NCT03524326 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-05-13

No results posted yet for this study

Summary

This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and cSCC.

Conditions

Interventions

DRUG

Lenvatinib Pill

24 mg oral daily

DRUG

Lenvatinib Pill

20 mg oral daily

DRUG

Lenvatinib Pill

14 mg oral daily

DRUG

Cetuximab

400mg/m2 IV, then 500mg/m2 IV weekly

DRUG

Lenvatinib Pill

10 mg oral daily

DRUG

Lenvatinib Pill

4 mg oral daily

Sponsors & Collaborators

Principal Investigators

  • Lara Dunn, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2022-10-13
Completion
2022-10-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03524326 on ClinicalTrials.gov